Low-Density Lipoprotein Cholesterol Is Predominantly Associated With Atherosclerotic Cardiovascular Disease Events in Patients With Evidence of Coronary Atherosclerosis: The Western Denmark Heart Registry
Overview
Authors
Affiliations
Background: Low-density lipoprotein cholesterol (LDL-C) is an important causal risk factor for atherosclerotic cardiovascular disease (ASCVD). However, a sizable proportion of middle-aged individuals with elevated LDL-C level have not developed coronary atherosclerosis as assessed by coronary artery calcification (CAC). Whether presence of CAC modifies the association of LDL-C with ASCVD risk is unknown. We evaluated the association of LDL-C with future ASCVD events in patients with and without CAC.
Methods: The study included 23 132 consecutive symptomatic patients evaluated for coronary artery disease using coronary computed tomography angiography (CTA) from the Western Denmark Heart Registry, a seminational, multicenter-based registry with longitudinal registration of patient and procedure data. We assessed the association of LDL-C level obtained before CTA with ASCVD (myocardial infarction and ischemic stroke) events occurring during follow-up stratified by CAC>0 versus CAC=0 using Cox regression models adjusted for baseline characteristics. Outcomes were identified through linkage among national registries covering all hospitals in Denmark. We replicated our results in the -funded Multi-Ethnic Study of Atherosclerosis.
Results: During a median follow-up of 4.3 years, 552 patients experienced a first ASCVD event. In the overall population, LDL-C (per 38.7 mg/dL increase) was associated with ASCVD events occurring during follow-up (adjusted hazard ratio [aHR], 1.14 [95% CI, 1.04-1.24]). When stratified by the presence or absence of baseline CAC, LDL-C was only associated with ASCVD in the 10 792/23 132 patients (47%) with CAC>0 (aHR, 1.18 [95% CI, 1.06-1.31]); no association was observed among the 12 340/23 132 patients (53%) with CAC=0 (aHR, 1.02 [95% CI, 0.87-1.18]). Similarly, a very high LDL-C level (193 mg/dL) versus LDL-C <116 mg/dL was associated with ASCVD in patients with CAC>0 (aHR, 2.42 [95% CI, 1.59-3.67]) but not in those without CAC (aHR, 0.92 [0.48-1.79]). In patients with CAC=0, diabetes, current smoking, and low high-density lipoprotein cholesterol levels were associated with future ASCVD events. The principal findings were replicated in the Multi-Ethnic Study of Atherosclerosis.
Conclusions: LDL-C appears to be almost exclusively associated with ASCVD events over ≈5 years of follow-up in middle-aged individuals with versus without evidence of coronary atherosclerosis. This information is valuable for individualized risk assessment among middle-aged people with or without coronary atherosclerosis.
Duan X, Zhang M, Sun X, Lin Y, Peng W Lipids Health Dis. 2025; 24(1):65.
PMID: 39985079 PMC: 11846231. DOI: 10.1186/s12944-025-02488-8.
Targeting fatty acid synthase reduces aortic atherosclerosis and inflammation.
Meade R, Ibrahim D, Engel C, Belaygorod L, Arif B, Hsu F Commun Biol. 2025; 8(1):262.
PMID: 39972116 PMC: 11840040. DOI: 10.1038/s42003-025-07656-1.
Guo S, Wang C, Hu T, Lan L, Ge Z, Huang J Clin Hypertens. 2025; 31:e7.
PMID: 39944936 PMC: 11800280. DOI: 10.5646/ch.2025.31.e7.
Zou Z, Sun Y, Zou L, Zhou Y, Lin X, Zhou J Diabetol Metab Syndr. 2025; 17(1):53.
PMID: 39940021 PMC: 11823151. DOI: 10.1186/s13098-025-01625-8.
Wang Y, Li Q, Bi L, Wang B, Lv T, Zhang P BMC Public Health. 2025; 25(1):310.
PMID: 39856644 PMC: 11763131. DOI: 10.1186/s12889-025-21588-9.